

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ernest P. Noble et al.	Examiner:	Unknown
Serial No.:	10/563,077	Group Art Unit:	1639
Filed:	December 29, 2005	Docket:	UCLA.154USWO
Title:	GENETIC MARKER OF RESPONSE TO ATYPICAL ANTIPSYCHOTICS AND ANTIDEPRESSANTS AND METHODS FOR USE THEREOF		

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being e-filed with the United States Patent and Trademark Office on September 6, 2006.

By: 

Name: Karen S. Canady

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 C.F.R. §1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

With regard to the above-identified application, the documents listed on the enclosed PTO Forms PTO/SB/08A and PTO/SB/08B are brought to the attention of the Examiner.

This statement should be considered under §1.97(b)(3) because it is submitted before the mailing date of a first Office Action on the merits. Accordingly, no fee or statement under §1.97(e) is required for consideration of the documents or other information listed on the enclosed forms.

In accordance with 37 C.F.R. §1.98(a)(2), a legible copy of each document or other information listed on the enclosed forms is provided, except issued U.S. Patents and Published Applications.

No representation is made that any listed document or other information is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art". Moreover, Applicants do


not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a listed document or other information is intended.

Consideration of the listed documents or other information is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached forms, marked as being considered and initialed by the Examiner, to the undersigned with the next Official Communication.

Please direct any response or inquiry to the below-signed attorney at (310) 966-9400.

Respectfully submitted,

Canady & Lortz
11340 W. Olympic Blvd, Suite 275
Los Angeles, California 90064
(310) 966-9400
Fax: (909) 494-4441

By: 
Name: Karen S. Canady
Reg. No.: 39927

Date: September 6, 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/563,077
Filing Date	12/29/05
First Named Inventor	Ernest P. Noble et al.
Art Unit	1639
Examiner Name	Not Yet Assigned
Attorney Docket Number	UCLA.154USWO

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	COMINGS, David A. et al., "The Dopamine D2 Receptor Locus as a Modifying Gene in Neuropsychiatric Disorders", JAMA, 266(13):1793-1800 (October 2, 1991).	
	2	MAKOFF, A.J. et al., "Association Study of Dopamine Receptor Gene Polymorphisms with Drug-induced Hallucinations in Patients...Disease", Pharmacogenetics, 10:43-48 (2000).	
	3	MIHARA, Kazuo et al., "Prolactin Response to Nemonapride, a Selective Antagonist for D2 like Dopamine Receptors...Gene", Psychopharmacology, 149:246-250 (2000).	
	4	MIHARA, Kazuo et al., "Relationship Between Taq1 A Dopamine D2 Receptor (DRD2) ... Bromperidol", Amer. J. of Medical Genetics (Neuropsychiatric Genetics) 105:271-274 (2001).	
	5	Seeman, Philip, "Atypical Antipsychotics: Mechanism of Action", W. Can J. Psychiatry, 47(1):29-35 (February 2002).	
	6	Suzuki, A. et al., "Association of the Taq1 A Polymorphism of the Dopamine D2 Receptor Gene with Predisposition...Syndromes", Am. J. Psychiatry, 158:1714-16 (2001).	
	7	Suzuki, A. et al., "The Relationship Between Dopamine D2 Receptor Polymorphism at the Taq1 A Locus and Therapeutic...Patients", Pharmacogenetics, 10(4):335-341 (June 2000).	
	8	Shafer, M., "Association of Short-term Response to Haloperidol Treatment with a Polymorphism in the Dopamine...Gene", Am. J. Psychiatry, 158:802-804 (2001).	

Examiner Signature	/Jeffrey Lundgren/	Date Considered	05/21/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.L./